Joint Exhibition of “Near-Future Breast Cancer Screening Through Breath Analysis” at Expo 2025 Osaka, Kansai
Shaping the Future
of
Medical Research
Medical Research
Technology for Life
Scroll
Revolutionizing testing standards by combining analytical technology with cutting-edge AI.
We are pursuing testing technologies that anyone can undergo at ease and aiming to achieve medical care that can detect diseases earlier and more reliably.
Non-invasive, accurate, and easy-to-take testing.
Our mission is to reduce the physical and psychological burdens that are associated with standard cancer testing as well as expand the accessibility for testing through research and development of non-invasive breath-based cancer screening technology.
News
News
Business
Making early cancer detection more accessible and gentle.
MediScan is engaged in research and development of non-invasive testing technology that enable early detection various cancers, initially starting with breast cancer, through advanced analysis of the components of VOCs (volatile organic compounds) present in exhaled breath.
-
Non-invasive, painless detection
-
Easy testing with
a single breath -
Highly accurate detection of biomarkers
Business
Business
Team
Expert Teams × Global Collaboration
Special Vice President, Chief of the Department of Hematology and Medical Oncology, and Director of the Precision Medicine Center
CEO Chairman
Specialization / AI & Algorithm Development
Specialization / AI & Algorithm
Specialization / Volatile Organic Compounds & GCMS
Specialization / Breast & Gynecological Surgery
HP / https://www.mcet.co.jp/
Expert Teams × Global Collaboration
Research and development system that creates
the future of medical care
Koichiro Yoshino
President & CEO (Chief Executive Officer)
After graduating from Iwate Medical University School of Medicine, he completed his residency at Toda Central General Hospital, followed by gaining clinical experience at Tokyo Medical University Hospital and Ibaraki Medical Center. He later on earned a Ph.D. in the field of oncology and then founded MediScan Co., Ltd. (formerly YOSHINO MEDICAL).
Motivated by the cancer diagnoses of both his parents, he expanded his activities to include reasearch on early cancer detection and medical device development.
Team Members
Masato Takaishi
Executive Vice President & COO (Chief Operating Officer)After obtaining an MBA in the United Kingdom, he accumulated nearly 20 years of industry experience at foreign medical device manufacturers including Sorin (now LivaNova) and St. Jude Medical (now Abbott Medical Japan). He possesses extensive experience across various functions including sales, education, customer service, and new business development, primarily focusing on Class IV medical devices.
Taku Kadowaki
CFO (Chief Financial Officer)After his tenure at Johnson & Johnson, he earned his MBA in the United States. He subsequently joined KPMG Financial Advisory in New York, where he was involved in M&A transactions across a broad range of industries, including plants, renewable energy, private equity, healthcare, pharmaceuticals, financial services, heavy industry, and TMT. He joined MediScan as CFO in 2024 after serving as Finance Director for start-ups, and now leads the company’s financial strategy and management.
Kotaro Shimizu
CAO (Chief Academic Officer)After graduating from Mie University School of Medicine, he practiced clinical medicine as an anesthesiologist and plastic surgeon. Leveraging his clinical experience, he began providing medical consulting services to corporations. In 2022, he founded Pons Inc. as President and Representative Director, developing video marketing and medical consulting businesses. Since 2022, he has also served concurrently as Director of MediScan Inc.
Daisuke Tanida
CSO (Chief Strategy Officer)Joined Tanida Seisakusho (now TANITA Corporation) in 1966. After serving in key positions including Director and General Manager of the Development Department, he was appointed President and Representative Director of TANITA Corporation in 1985. He developed and launched the world's first home-use body fat scale and body composition analyzer, transforming the company from a deficit position into the world's number one health meter sales company. During his tenure, he established companies and served as representative in major countries overseas. He also served as Director of TANITA Research Institute.
Tomohiro Myojo
Tokyo Cancer Immunotherapy CenterSpecial Vice President, Chief of the Department of Hematology and Medical Oncology, and Director of the Precision Medicine Center
Special Vice President of the Tokyo Cancer Immunotherapy Center, Chief of the Department of Hematology and Medical Oncology, and Director of the Precision Medicine Center. After graduating from Kumamoto University School of Medicine and completing his residency at Okayama University Hospital, he trained in hematologic malignancies and cancer chemotherapy at Kure Kyosai Hospital, Toranomon Hospital, and The Cancer Institute Hospital of JFCR. He has been working at Edogawa Hospital since 2009. He obtained board certification in hematology and became the youngest physician to be certified as a board-certified medical oncologist in Japan. His specialties include hematologic diseases, cancer pharmacotherapy, and infection control.
Collaborator In Israel
Moshe Feldman
VOCs Medical Ltd.CEO Chairman
Moshe Feldman studied Business Management at Open University in Israel. With 24 years of experience living in Japan, he achieved a 3rd-degree black belt in Karate at Master Haragaki's Dojo in Tokyo. He served at the Israeli Embassy in Japan for two years, engaging in international relations. In 2008, he founded River Enterprise Ltd., a consulting firm supporting collaboration between companies and investment firms to introduce innovative technologies and products into the Japanese market. With expertise in product management and marketing, combined with deep understanding of Japanese business culture, he has built effective long-term partnerships. River Enterprise has established a productive partnership with the Japan-Israel Business Association (JIBA), which includes over 400 major Japanese companies. In 2016, he founded VOC Medical Ltd., promoting the development of breast cancer detection technology through breath analysis. The company's mission is to provide effective solutions for breast cancer detection and contribute to the world with innovative technology of the highest caliber.
Dr. Gal Ben-David
VOCs Medical Ltd. CTOSpecialization / AI & Algorithm Development
After obtaining his B.Sc. (Summa Cum Laude), M.Sc., and Ph.D. in Electrical Engineering, specializing in communications and digital signal processing, Dr. Ben-David also earned an M.Sc. in Business Administration. Starting in 1993, he led the development of natural language processing software as VP of R&D at Product Computers. In 1997, he served as VP of Engineering at Itamar Medical, where he engaged in medical device research and development as well as CE, FDA, and ISO regulatory compliance activities. From 2006, he served as CEO of OBTools Ltd., overseeing electronic device development and medical device regulatory compliance for fetal monitors. In 2002, he founded Dr. Gal Ben-David DSP Ltd., providing consulting and development services in the field of digital signal processing (ISO9001 and ISO13485 certified). Since 2018, he has also served as CTO at VOC Medical, promoting the development of disease diagnostic technology through breath analysis. Since 1995, he has taught digital signal processing and image processing as an adjunct lecturer at the Technion. He has co-authored 19 patents worldwide.
Dr. Daniel Moskovich
Research Team Member (Israel)Specialization / AI & Algorithm
After obtaining his Ph.D. in Mathematics from Kyoto University, Dr. Moskovich served as a JSPS Postdoctoral Researcher at the Research Institute for Mathematical Sciences at Kyoto University, followed by research positions at the University of Toronto, Nanyang Technological University, and Ben-Gurion University, where he conducted research in low-dimensional topology and information theory. Leveraging his extensive academic research experience, he transitioned to the machine learning and signal processing fields in the technology industry in 2016. At Lightricks Ltd., he developed image processing technology using CNNs. At Neteera Technologies Ltd., he developed algorithms for extracting vital signs from radar signals. Since 2020, he has served as Head of Algorithms at C2A Security, leading the development of statistical analysis of sensor signals and cyberattack detection systems. Since 2025, he has also served as an Advisor at VOC Medical, engaging in research and development of disease screening technology through breath analysis.
Dr. Igal Gozlan
Tel Aviv UniversitySpecialization / Volatile Organic Compounds & GCMS
After obtaining his B.Sc. in Chemistry and M.Sc. in Organic Chemistry from the Hebrew University of Jerusalem, Dr. Gozlan earned his Ph.D. in Environmental Science from Tel Aviv University. Following his work as a research scientist at Teva Pharmaceutical Industries in the organic synthesis of pharmaceutical active ingredients, he joined Israel Chemicals Ltd. (ICL) TAMI Central R&D Institute in 1985, where he served as Analytical Instrumentation Lab Manager, leading structural analysis of organic compounds and development of various analytical methods using HPLC, LC/MS, and GC/MS. He has engaged in analytical method development and validation across a wide range of fields including pharmaceuticals, environment, food, fragrances, and pesticides. He has served as an executive committee member of the Israeli Analytical Chemistry Society since 1997 and as chairman of the society's annual meeting in 2017. Since 2019, he has worked as an independent analytical consultant while serving as Senior Analytical Chemist at the Water Research Center at Tel Aviv University. Since 2002, he has been engaged in teaching chromatography and spectroscopy at TAMI Institute and Bioforum at Weizmann Science Park. He has published over 37 academic papers on pharmaceutical degradation products and aquatic environmental contamination.
Collaborator
Sadako Akashi
Tokyo Women's Medical UniversitySpecialization / Breast & Gynecological Surgery
After graduating from the Faculty of Medicine at The University of Tokyo, Professor Akashi joined the Third Department of Surgery at the same University Hospital. She completed her surgical residency at the National Cancer Center Hospital and served as a clinical fellow in breast oncology as well as the ward chief. In 2010, she became the Chief of the Outpatient Breast and Medical Oncology Department. She was appointed as Associate Professor of Breast Surgery at Showa University School of Medicine in 2011, and promoted to Professor in 2019. Since September 2022, she has served as a professor and the Director of the Department of Breast Surgery at Tokyo Women's Medical University, leading the development of the newly established Breast Surgery Department. As a breast surgery professional whose expertise attracts patients from across the nation, she has performed approximately 3,000 breast cancer surgeries. She received the 5th Japanese Breast Cancer Society Research Award in 1999 and the Chikayo Chikamatsu Award from Soroptimist International of Japan Foundation in 2019. She currently serves concurrently as a board member of the Japanese Breast Cancer Society. Professor Akashi is dedicated to providing comprehensive breast cancer treatment tailored to each individual patient.
MC EVATECH Co., Ltd.
Breath Analysis Machine for Clinical TrialsHP / https://www.mcet.co.jp/
Redefining Cancer Detection
Team
Team
Company
Company Overview
- Company Name
- MediScan Co., Ltd.
- President
- Koichiro Yoshino
- Location
- Ginza Astel Bldg, 7-2-6 Ginza, Chuo-ku, Tokyo 104-0061 Japan
GoogleMap - Phone Number
- +81-3-6280-6895
- Establishment
- July 7, 2021
- Capital
- 671.7 million yen (including capital reserves)
as of February 28, 2025 - Business Content
- Clinical development/manufacturing and marketing of breath-based breast cancer test
Online medical consultation services
Clinic management consulting services - Main Trading Partners
- VOCs MEDICAL LTD.
YAMATE Co., Ltd.
MDT Japan Co., Ltd.
FAIMStech JAPAN Co., Ltd.
first step toward
a smarter future
in medical care
For inquiries about our services, interviews, etc., please use the link button below.
Contact Us